Lunsumio – Talk Bio

Actionable Insights Powered by AI

Roche Bags EU Nod for SC Formulation of Lunsumio, Re-Igniting Bispecific Battle with Tepkinly

3 weeks ago talkbio0Tagged Antibodies, Bispecific, Approved, Clinical Research, Conditional, EU, GO29781, Lunsumio, Lymphoma, Follicular, marketing authorisation, Relapsed/Refractory, Roche (company), subcutaneous, Tepkinly

Roche; Lunsumio; subcutaneous; EU approval; conditional marketing authorisation; follicular lymphoma; bispecific antibody; Tepkinly; CD20xCD3; relapsed/refractory; GO29781 study

AbbVie’s Epkinly Enters Follicular Lymphoma Market, Competing with Roche’s Lunsumio

1 year ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Approved, Cancer Therapeutic Procedure, Lunsumio, Lymphoma, Follicular, Roche (company), United States Food and Drug Administration

Epkinly, Lunsumio, follicular lymphoma, bispecific antibodies, AbbVie, Roche, FDA approval, cancer treatment